The Personalized Immunotherapy Research Lab (PIRL) is a multi-investigator research group at the University of North Carolina’s School of Medicine, whose members bring together expertise in immunology, genomics, oncology, and machine learning. We work on developing cancer immunotherapies that use a patient’s immune system to attack tumor-specific targets. We are committed to open science through building open source research software, making experimental data unconditionally available, and disseminating results quickly through blog posts and preprints.
What will make personalized cancer vaccines more effective? With support from the OpenAI Foundation, PIRL is launching the Initiative for Generative Immunotherapy at UNC. The initiative will release data connecting tumor mutations, presented antigens, and T-cell responses, alongside a clinical trial comparing vaccine formulations to help improve target selection and immune responses.
The latest RAFT and LENS releases simplify installation, workflow configuration, and results review. They bring more reliable cloud execution, automatic resource scaling, and expanded quality control, plus tiered tumor antigen reports that help researchers distinguish the full set of predictions from candidates with stronger supporting evidence.
The problems aren't all solved yet...
Using single-cell data to examine variation in tumor antigen expression.
Extending a shared representation of variants to RNA.
Explaining the orientation of inversion breakpoints.
New posts are announced by email. Subscribe on Substack or follow the RSS feed.
